ArticleCureus2026
Differential Improvement in Obsessive Rumination and Fantasy Intrusions Versus Attachment-Related Emotional Dysregulation During Oral Glutamatergic Augmentation in a 16-Year-Old Adolescent.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 16-year-old post-pubertal female presented with mixed anxiety-depressive symptoms, prominent obsessive rumination, relationship-centered guilt, reassurance-seeking, fantasy intrusions, and difficulty separating fantasy from reality during periods of distress. Baseline scores were in the moderate range for depression and severe range for anxiety, with a Patient Health Questionnaire-9 score of 14 and a Generalized Anxiety Disorder-7 score of 20. A low-to-moderate-intensity Cheung glutamatergic regimen-like strategy was introduced, consisting of dextromethorphan, a CYP2D6-inhibiting antidepressant, and piracetam, with risperidone co-prescribed for fantasy-related cognitions, overvalued ideas, and obsessive instability. Across the follow-up period from January to June 2026, depressive symptoms improved to the minimal-to-mild range, and anxiety symptoms improved to the mild range, with Patient Health Questionnaire-9 scores mostly between 4 and 6 and Generalized Anxiety Disorder-7 scores mostly between 6 and 7, except for one stress-related rise to 11. Obsessional symptoms reportedly reduced by more than 30% after dextromethorphan escalation and piracetam introduction. Later improvements included better ability to interrupt rumination, reduced preoccupation with "pretending to be ill," shorter fantasy intrusions, and improved fantasy-reality differentiation. No medication side effects, dissociation, hypomania, serotonin-toxicity symptoms, sleep disruption, appetite loss, or renewed self-harm ideation were documented. The clinically distinctive feature was a discordant response pattern as follows: repetitive, obsessive, and fantasy-related intrusions appeared to loosen more clearly than attachment-linked emotional reactivity. The course is compatible with the hypothesis that N-methyl-D-aspartate and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (NMDA-AMPA) modulation may help selected post-pubertal adolescents disengage from rigid perseverative loops. However, interpretation is limited by polypharmacy, risperidone titration, selective serotonin reuptake inhibitor (SSRI) effects, supportive care, natural symptom fluctuation, and the absence of formal obsessive-compulsive ratings or withdrawal/rechallenge. This case is best viewed as hypothesis-generating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.